Clinical value of Antibody D5F3 and Survivin in patients with non- small cell lung cancer
10.3969/j.issn.1005-1678.2017.09.168
- VernacularTitle:抗体D5F3及Survivin在非小细胞肺癌患者中的临床应用价值分析
- Author:
Fei HUANG
;
Yuna GUO
- Keywords:
Non-small cell lung cancer;
EML4-ALK;
D5F3;
Survivin;
diagnosis
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(9):377-378,381
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical value of D5F3 and Survivin in patients with non-small cell lung cancer. Methods 100 patients with non - small cell lung cancer admitted in our hospital from January 2016 to June 2017 were examined by immunohistochemical method, to analyze the clinical value of D5F3 and Survivin antibody in non - small cell lung cancer (NSCLC). Results The coincidence rate of D5F3 was (20％), (++) was 33.33％, and the coincidence rate was (87.50％), and the difference was statistically significant (P<0.05). The positive rate of Survivin protein expression was correlated with the differentiation degree of non-small cell lung cancer, TNM stage and lymph node metastasis (P<0.05). Conclusion D5F3 has high accuracy, sensitivity and specificity, and has important clinical diagnostic value; The detection of Survivin expression is helpful for clinical differentiation, clinical staging and lymph node metastasis in patients with non-small cell lung cancer.
